Objective:To compare the efficacy and safety of ticagrelor tablets produced by Zhejiang Hisun Pharmaceutical Co., Ltd. (the generic drug) and ticagrelor tablets produced by AstraZeneca Pharmaceutical Co., Ltd. (the original drug) in antiplatelet therapy.Methods:The study design was a retrospective cohort study. The subjects were patients who underwent percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) and postoperative antiplatelet therapy with ticagrelor tablets at First Affiliated Hospital of Dalian Medical University during January 2020 to July 2021. Through the hospital electronic medical record system, relevant clinical data of patients (age, gender, comorbidities, blood lipid level on admission, PCI indications, antiplatelet treatment regimen, efficacy and safety assessment endpoint events within 12 months of treatment, etc.) were collected. The patients were divided into the generic drug group and the original drug group. To exclude confounders, propensity score matching (PSM) method was used. The efficacy evaluation index was the incidence of the primary endpoint events (cardiogenic death, stroke, target revascularization, recurrent infarction) and secondary endpoint events (all-cause mortality, peripheral artery occlusion, stent thrombosis, angina attacks) within 12 months of treatment. The safety evaluation index was the incidence of bleeding event within 12 months of treatment.Results:A total of 1 486 patients were included in this study, including 734 in the generic drug group and 752 in the original drug group. The proportion of women and unstable angina, and the level of high-density lipoprotein cholesterol were higher than those in the original drug group (all P<0.05). The proportion of patients with hyperlipidemia and ST-segment elevation myocardial infarction were lower than those in the original drug group (both P<0.05). After PSM, 690 patients were enrolled in the generic drug group and 690 patients in the original drug group (all P>0.05). No differences in the comparison of clinical features between the 2 groups was significant (all P>0.05). No differences in the incidences of primary endpoints, secondary endpoints, and bleeding events between the 2 groups was significant before and after PSM [before PSM: 12.1%(89/734) vs. 10.9%(82/752), 10.8%(79/734) vs. 8.4%(63/752), 0.3%(2/734) vs. 0.5%(4/752); after PSM: 12.6%(87/690) vs. 12.3%(85/690), 11.0%(76/690) vs. 8.3%(57/690), 0.3%(2/690) vs. 0.4%(3/690); all P>0.05]. No death occurred in patients of both groups. Bleeding is predominantly characterized by epistaxis and subcutaneous petechiae, which did not lead to interruption of antiplatelet therapy. Conclusion:The efficacy and safety of ticagrelor tablets produced by Zhejiang Hisun Pharmaceutical Co., Ltd. for antiplatelet therapy in ACS patients after PCI surgery were basically the same as those of the original drug.

目的 总结临床药师参与1例胰腺癌伴糖尿病患者胰十二指肠切除术后治疗的药学实践.方法 临床药师协助临床医师选择糖尿病患者胰十二指肠切除术后治疗药物,为患者提供合理治疗方案.结果 患者术后感染症状体征明显好转,达到满意的治疗效果.结论 临床药师参与临床治疗实践,规范围术期抗菌药物的选择,提高了胰腺癌合并糖尿病患者术后继发腹腔感染的药物治疗水平.

目的:探讨PKCδ在丹酚酸B(SalB)抗对乙酰氨基酚(APAP)肝损伤中的作用.方法:通过MTT法、细胞内还原型GSH含量测定、细胞LDH溢出量测定检测SalB抗APAP肝损伤作用.Western Blot法检测SalB对Nrf2核移位的影响.应用PKCδ抑制剂或siRNA干扰技术,探索PKδ在SalB抗APAP肝损伤中的作用,Western Blot法检测PKCδ表达及Nrf2激活.结果:SalB可明显减轻APAP造成的HepG2细胞损伤,同时激活PKCδ,促进Nrf2核移位.PKCδ选择性阻断剂Rottlerin可减弱以上保护作用.PKCδ敲除明显减弱SalB对Nrf2核移位的诱导作用.结论:SalB可减轻APAP所致肝细胞损伤,其机制与SalB通过PKCδ激活Nrf2通路有关.